June 2008 in “Drugs & therapy perspectives” Dutasteride effectively treats benign prostatic hyperplasia, improving symptoms and quality of life.
January 2026 in “RSC Advances” Epristeride's metabolism in zebrafish helps improve doping detection methods.
September 2003 in “Reactions Weekly”
20 citations
,
June 2007 in “Recent Patents on Endocrine, Metabolic & Immune Drug Discovery” Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.
November 2025 in “Drug Testing and Analysis” Epristeride's metabolism involves key metabolites and proteins, affecting its use in doping tests.
May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly” 27 citations
,
July 2008 in “The Journal of Steroid Biochemistry and Molecular Biology” The new compounds may be more effective and cheaper than current treatments for conditions like baldness.
January 2026 in “Andrology” PRP injections are safe but don't significantly improve Peyronie's Disease.
April 2011 in “ChemInform” A new compound may effectively inhibit the enzyme linked to BPH and hair loss.
5 citations
,
January 2014 in “Molecular Simulation” A new compound may treat benign prostatic hyperplasia better than finasteride.
August 2009 in “Australian Prescriber” Dutasteride is approved to help manage prostate enlargement.
1 citations
,
February 2022 in “The Journal of Urology” Certain drugs like Dutasteride and Finasteride might help fight SARS-CoV-2 by increasing levels of a steroid called DHEA, which can protect the heart and increase nitric oxide to counteract the virus.
3 citations
,
September 2020 in “Bladder cancer” 5α-reductase inhibitors don't stop bladder cancer from developing or getting worse.
7 citations
,
January 2013 in “European Urology” 5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.
March 2005 in “Current Prostate Reports”
2 citations
,
March 2016 in “The Journal of Urology” Finasteride 1mg linked to diverse symptoms; other treatments improve erectile function in rats.
46 citations
,
March 2001 in “Journal of endocrinological investigation” 5α-reductase inhibitors, like finasteride and dutasteride, effectively treat BPH, male baldness, and hirsutism, with potential for acne and prostate cancer prevention.
13 citations
,
January 2005 in “Chemical and Pharmaceutical Bulletin” Smaller substituents at C-17 enhance the inhibitory activity of progesterone derivatives on 5alpha-reductase.
May 2024 in “Reactions weekly” 1 citations
,
October 2013 in “Urology” More men are using medication for benign prostatic hyperplasia, influenced by marketing and FDA approvals.
6 citations
,
January 2003 in “PubMed” Finasteride reduces prostate size and symptoms with few side effects.
21 citations
,
January 2017 in “Dermatology Online Journal” Finasteride and dutasteride can cause sexual problems like impotence and low libido.
June 2026 in “Frontiers in Medicine” 5α-reductase inhibitors for hair loss can cause mild, reversible sexual side effects in some men.
237 citations
,
December 2001 in “Urology” Blocking the enzyme 5α-reductase can shrink the prostate and help treat enlarged prostate issues.
December 2005 in “Current Prostate Reports” In 2005, men used finasteride mainly to treat an enlarged prostate.
15 citations
,
January 2017 in “Experimental Neurology” Finasteride reduces movement issues in Parkinson's disease rats.
21 citations
,
October 2015 in “Current Drug Targets” Both dutasteride and finasteride improve urinary symptoms, but dutasteride may be better at reducing the risk of prostate surgery and sudden inability to urinate.
13 citations
,
August 2007 in “Bioorganic & medicinal chemistry letters” A new compound effectively inhibits human 5α-reductase 1.
1 citations
,
January 2015 in “Sexual Medicine Reviews” Current treatments for recurrent ischemic priapism are not well-defined and need more research.